Trial Profile

First line Lutetium-177-PSMA-617 radioligand therapy in metastatic castrate resistant prostate cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jun 2022 Status changed from suspended to recruiting, according to a Novartis media release.
30 Jun 2022 According to a Novartis media release, company has remediated the issues that led to the temporary, voluntary suspension. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified.Company restarted screening and enrollment for clinical trials with 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan) in the US, in most countries globally.
05 May 2022 According to Novartis media release, Novartis is putting a temporary hold on screening and enrollment for 177Lu-PSMA-617 clinical trials globally, hence status changed to suspended.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com